Touraine J L, Roncarolo M G, Bacchetta R, Raudrant D, Rebaud A, Laplace S, Cesbron P, Gebuhrer L, Zabot M T, Touraine F
Department of Transplantation and Clinical Immunology, Hôpital Edouard Herriot, Lyon, France.
Bone Marrow Transplant. 1993;11 Suppl 1:119-22.
Over the last 18 years, we have developed the transplantation of fetal liver cells to treat severe immunodeficiencies, hematological disorders and inborn errors of metabolism. Post-natally, this treatment is successful in two-third of patients and it is therefore very valuable, especially when there is no perfectly matched donor for a bone marrow transplant. Since 1988 we have carried out these fetal liver transplants (FLTs) in utero, immediately after prenatal diagnosis. Engraftment and reconstitution have been obtained, and several advantages appear to be associated with in utero FLT: increased probability of graft take, ideal isolation of the patient (in the maternal uterus) and optimal environment for the differentiation of the transplanted fetal liver cells (in the fetal host).
在过去的18年里,我们已开展了胎儿肝细胞移植,用于治疗严重免疫缺陷、血液系统疾病和先天性代谢紊乱。出生后,这种治疗方法在三分之二的患者中取得了成功,因此非常有价值,尤其是在没有完全匹配的骨髓移植供体的情况下。自1988年以来,我们在产前诊断后立即进行了宫内胎儿肝移植(FLT)。已实现植入和造血重建,宫内FLT似乎具有几个优点:移植成功的概率增加、患者(在母体内)得到理想的隔离以及移植的胎儿肝细胞(在胎儿宿主中)分化的最佳环境。